Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03824535 · ClinicalTrials.gov registry record · Phase 2
18F-FSPG PET/CT in Diagnosing Early Lung Cancer in Patients With Lung Nodules
A Phase 2 study of Cigarette Smoker and Multiple Pulmonary Nodules, sponsored by Andrei Iagaru.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT03824535 is a Phase 2 study of Cigarette Smoker and Multiple Pulmonary Nodules that has completed, run by Andrei Iagaru. The registered enrollment target is 15 participants, below the 913-participant average among 5 other Cigarette Smoker trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03824535, a Phase 2 study of Cigarette Smoker and Multiple Pulmonary Nodules, has completed, sponsored by Andrei Iagaru.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies how well 18F-FSPG positron emission tomography (PET)/computed tomography (CT) work in diagnosing early lung cancer in patients with indeterminate lung nodules. PET imaging with an imaging agent called 18F-FDG is often used in combination with a PET/CT scanner to evaluate cancers. Giving 18F-FSPG before a PET/CT scan may work better in helping researchers diagnose early lung cancer in patients with lung nodules.
Conditions Studied
Interventions
- DRUG Fludeoxyglucose F-18
- DIAGNOSTIC_TEST Computed Tomography
- DRUG Fluorine F 18 L-glutamate Derivative BAY94-9392
- DIAGNOSTIC_TEST Positron Emission Tomography (PET/CT)
Study Locations (1)
California
- Stanford Cancer Institute Palo Alto - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2019-02-04 |
| Est. Completion | 2021-07-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03824535
The ClinicalTrials.gov registry entry for NCT03824535 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 913-participant average among 5 other Cigarette Smoker trials with a reported enrollment target (98% lower). The listed sponsor is Andrei Iagaru, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Cigarette Smoker appearing as the primary indexed condition, and to 4 interventions - of which Fludeoxyglucose F-18 is the first listed.
NCT03824535 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03824535 about?
NCT03824535 is a clinical study titled "18F-FSPG PET/CT in Diagnosing Early Lung Cancer in Patients With Lung Nodules". This phase II trial studies how well 18F-FSPG positron emission tomography (PET)/computed tomography (CT) work in diagnosing early lung cancer in patients with indeterminate lung nodules. PET imaging with an imaging agent called 18F-FDG is often used in combination with a PET/CT scanner to evaluate ...
What is the current status of trial NCT03824535?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2019-02-04. Estimated completion is 2021-07-30.
What conditions does trial NCT03824535 study?
This clinical trial studies the following conditions: Cigarette Smoker, Multiple Pulmonary Nodules, Pulmonary Nodule, Current Smoker, Former Smoker.
What interventions are being tested in trial NCT03824535?
The interventions under investigation include: Fludeoxyglucose F-18 (DRUG), Computed Tomography (DIAGNOSTIC_TEST), Fluorine F 18 L-glutamate Derivative BAY94-9392 (DRUG), Positron Emission Tomography (PET/CT) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03824535?
This trial is sponsored by Andrei Iagaru, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03824535 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cigarette Smoker
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer
RECRUITING · NA
-
Behavioral Activation Therapy and Nicotine Replacement Therapy in Increasing Smoking Cessation
ACTIVE NOT RECRUITING · NA
-
rTMS in Promoting Smoking Cessation and Preventing Relapse in Current Smokers
ACTIVE NOT RECRUITING · NA
-
Varenicline and Combined NRT for Smoking Cessation
ACTIVE NOT RECRUITING · Phase 4
-
Validation of Biomarkers of Exposure and Host Response
COMPLETED · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.